{"id":953545,"date":"2026-04-22T06:20:01","date_gmt":"2026-04-22T10:20:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/"},"modified":"2026-04-22T06:20:01","modified_gmt":"2026-04-22T10:20:01","slug":"kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/","title":{"rendered":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader"},"content":{"rendered":"

<\/p>\n

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader<\/b><\/p>\n

The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences\u2019 development and manufacturing capabilities with Amneal Pharmaceuticals\u2019 commercial strengths<\/i><\/p>\n

Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines<\/i><\/p>\n

PISCATAWAY, N.J.–(BUSINESS WIRE<\/a>)–
\nKashiv BioSciences, LLC (\u201cKashiv\u201d), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (\u201cAmneal\u201d). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260421283753\/en\/<\/a><\/p>\n

\nThis acquisition combines Kashiv\u2019s extensive expertise in the development and manufacturing of biosimilars with Amneal\u2019s scale and commercialization capabilities. Kashiv is headquartered in Piscataway, New Jersey with operations in the U.S. and India. Amneal is headquartered in Bridgewater, New Jersey, and is a leading biopharmaceutical company with one of the largest affordable medicine businesses in the U.S.<\/p>\n

\nTogether, the companies will establish a fully integrated biosimilar platform at scale, to deliver high-quality, affordable therapies, expand patient access, and strengthen their position in the global biopharmaceutical landscape.<\/p>\n

\n\u201cWe are thrilled to combine Kashiv\u2019s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S.,\u201d said<\/b>Dr. Sandeep Athalye, Chief Executive Officer at Kashiv.<\/b> \u201cOur companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our partnership of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies.\u201d<\/p>\n

\n\u201cAs biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market,\u201d said Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal. <\/b>\u201cWith Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation.\u201d<\/p>\n

\n\u201cThis acquisition establishes Amneal as a fully integrated global biosimilar platform at scale,\u201d said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal. <\/b>\u201cBy combining Kashiv\u2019s deep R&D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth.\u201d<\/p>\n

\nJ.P. Morgan is serving as Kashiv\u2019s financial advisor for the transaction, Holland & Knight LLP is serving as legal counsel, and Dhinal Shah Associates is serving as India legal counsel.<\/p>\n

About Kashiv BioSciences
\n
<\/b>Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, \u201cKashiv BioSciences\u201d) operates with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For additional information, please visit kashivbiosciences.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

About Amneal
\n
<\/b>Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel and built on the belief that innovation only matters if it\u2019s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson\u2019s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260421283753\/en\/<\/a><\/span><\/p>\n

For Kashiv BioSciences:
\n<\/b>
Ross Oehler
\n
Chief Legal Officer
\n
ross.oehler@kashivbio.com
\n<\/a><\/p>\n

For Amneal Pharmaceuticals:
\n<\/b>
Anthony DiMeo
\n
VP, Investor Relations
\n
anthony.dimeo@amneal.com
\n<\/a><\/p>\n

Brandon Skop
\n
Sr. Director, Corporate Communications
\n
brandon.skop@amneal.com<\/a><\/p>\n

KEYWORDS:<\/b> New Jersey United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Other Science General Health Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences\u2019 development and manufacturing capabilities with Amneal Pharmaceuticals\u2019 commercial strengths Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines PISCATAWAY, N.J.–(BUSINESS WIRE)– Kashiv BioSciences, LLC (\u201cKashiv\u201d), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (\u201cAmneal\u201d). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This press release features multimedia. View the full release … <\/p>\n

Continue reading “Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-953545","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences\u2019 development and manufacturing capabilities with Amneal Pharmaceuticals\u2019 commercial strengths Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines PISCATAWAY, N.J.–(BUSINESS WIRE)– Kashiv BioSciences, LLC (\u201cKashiv\u201d), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (\u201cAmneal\u201d). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This press release features multimedia. View the full release … Continue reading "Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-22T10:20:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader\",\"datePublished\":\"2026-04-22T10:20:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/\"},\"wordCount\":839,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/\",\"name\":\"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-22T10:20:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/","og_locale":"en_US","og_type":"article","og_title":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Market Newsdesk","og_description":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences\u2019 development and manufacturing capabilities with Amneal Pharmaceuticals\u2019 commercial strengths Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines PISCATAWAY, N.J.–(BUSINESS WIRE)– Kashiv BioSciences, LLC (\u201cKashiv\u201d), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (\u201cAmneal\u201d). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This press release features multimedia. View the full release … Continue reading \"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-22T10:20:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader","datePublished":"2026-04-22T10:20:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/"},"wordCount":839,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/","name":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-22T10:20:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260421283753r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kashiv-biosciences-agrees-to-be-acquired-by-amneal-pharmaceuticals-to-create-a-fully-integrated-global-biosimilar-leader\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/953545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=953545"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/953545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=953545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=953545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=953545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}